Population‐based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa

Epidemiology data regarding hidradenitis suppurativa (HS) are conflicting and prevalence estimates vary 80‐fold, from 0·05% in a population‐based study to 4%.

[1]  G. Jemec.  The symptomatology of hidradenitis suppurativa in women , 1988, The British journal of dermatology.

[2]  J. Raeburn,et al.  The clinical genetics of hidradenitis suppurativa revisited , 2000, The British journal of dermatology.

[3]  C. Holman,et al.  Improved methods for estimating incidence from linked hospital morbidity data. , 2003, International journal of epidemiology.

[4]  D. Ashcroft,et al.  Interventions for vitiligo. , 2006, The Cochrane database of systematic reviews.

[5]  Joseph M Kist,et al.  Hidradenitis suppurativa: an update. , 2007, Advances in dermatology.

[6]  O. Faye,et al.  Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. , 2008, Journal of the American Academy of Dermatology.

[7]  Raphael Kopan.  Faculty Opinions recommendation of Gamma-secretase gene mutations in familial acne inversa. , 2010 .

[8]  Baoxi Wang,et al.  γ-Secretase Gene Mutations in Familial Acne Inversa , 2010, Science.

[9]  M. Simpson,et al.  Mutations in the γ-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). , 2012, The Journal of investigative dermatology.

[10]  G. Jemec.  Clinical practice. Hidradenitis suppurativa. , 2012, The New England journal of medicine.

[11]  A. Weaver,et al.  Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. , 2013, The Journal of investigative dermatology.

[12]  P. Stang,et al.  Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. , 2013, Journal of the American Academy of Dermatology.

[13]  A. Weaver,et al.  Prevalence of Hidradenitis Suppurativa: A Population-Based Study in Olmsted County, Minnesota , 2014, Dermatology.

[14]  A. Kimball,et al.  The validity of the diagnostic code for hidradenitis suppurativa in an electronic database , 2014, The British journal of dermatology.

[15]  A. Kimball,et al.  Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. , 2014, Journal of the American Academy of Dermatology.

[16]  David Moher,et al.  The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines , 2015, PloS one.

[17]  J. Lapins,et al.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  S. Halevy,et al.  Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[19]  G. Jemec,et al.  A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values , 2015, Patient related outcome measures.

[20]  K. Hood,et al.  Interventions for hidradenitis suppurativa. , 2015, The Cochrane database of systematic reviews.

[21]  J. Lapins,et al.  Diagnostic delay in hidradenitis suppurativa is a global problem , 2015, The British journal of dermatology.

[22]  K. Bhaskaran,et al.  Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.

[23]  P. Wolkenstein,et al.  Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta‐analysis of observational studies , 2015, The British journal of dermatology.

[24]  G. Gislason,et al.  Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. , 2016, JAMA dermatology.

[25]  J. Dreiher,et al.  Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Cross-Sectional Study of 3,207 Patients. , 2016, The Journal of investigative dermatology.

[26]  G. Jemec,et al.  Disutility in Patients with Hidradenitis Suppurativa: A Cross-sectional Study Using EuroQoL-5D. , 2016, Acta dermato-venereologica.

[27]  J. Ring,et al.  Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)‐syndrome: a new entity within the spectrum of autoinflammatory syndromes? , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[28]  J. Kirby,et al.  Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States , 2017, JAMA dermatology.

[29]  A. Garg,et al.  Incidence of hidradenitis suppurativa in the United States: A sex‐ and age‐adjusted population analysis , 2017, Journal of the American Academy of Dermatology.

[30]  P. Riis,et al.  Patients with hidradenitis suppurativa have no increased risk of Alzheimer disease , 2017, The British journal of dermatology.